Xeris Biopharma (XERS) to Release Quarterly Earnings on Monday

Xeris Biopharma (NASDAQ:XERS) is expected to be releasing its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect the company to announce earnings of $0.03 per share and revenue of $86.00 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Monday, March 2, 2026 at 8:30 AM ET.

Xeris Biopharma Price Performance

NASDAQ XERS opened at $6.12 on Friday. Xeris Biopharma has a 12 month low of $3.59 and a 12 month high of $10.08. The company has a market capitalization of $1.02 billion, a P/E ratio of -61.19 and a beta of 0.52. The company’s 50 day simple moving average is $7.23 and its 200 day simple moving average is $7.64.

Insider Buying and Selling

In other news, Director John Johnson sold 135,400 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $7.22, for a total value of $977,588.00. Following the completion of the sale, the director owned 698,083 shares in the company, valued at $5,040,159.26. This represents a 16.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider John Patrick Shannon, Jr. sold 24,907 shares of Xeris Biopharma stock in a transaction on Monday, January 5th. The shares were sold at an average price of $7.08, for a total value of $176,341.56. Following the transaction, the insider owned 2,705,346 shares in the company, valued at $19,153,849.68. This represents a 0.91% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 240,308 shares of company stock valued at $1,745,120. 6.47% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Xeris Biopharma

A number of large investors have recently made changes to their positions in the business. Cetera Investment Advisers lifted its position in shares of Xeris Biopharma by 3.9% in the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock worth $216,000 after purchasing an additional 1,735 shares in the last quarter. Royal Bank of Canada increased its stake in Xeris Biopharma by 6.5% in the 4th quarter. Royal Bank of Canada now owns 38,636 shares of the company’s stock valued at $304,000 after buying an additional 2,351 shares during the period. Kestra Advisory Services LLC purchased a new stake in Xeris Biopharma in the 4th quarter worth approximately $25,000. The Manufacturers Life Insurance Company boosted its stake in shares of Xeris Biopharma by 7.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 54,472 shares of the company’s stock valued at $254,000 after buying an additional 3,562 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after buying an additional 3,594 shares during the period. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on XERS. Oppenheimer reaffirmed an “outperform” rating and issued a $18.00 price target on shares of Xeris Biopharma in a report on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Xeris Biopharma in a report on Wednesday, January 21st. Piper Sandler boosted their target price on Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. Finally, Barclays assumed coverage on Xeris Biopharma in a research report on Monday, December 8th. They issued an “overweight” rating and a $9.00 price target for the company. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.08.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.